Mitochondrial Drug Targets in Cell Death and Cancer

Author(s): Gustavo Ferrin, Clara I. Linares, Jordi Muntane

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 20 , 2011

Become EABM
Become Reviewer
Call for Editor


Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cells. The present review is focused on the different experimental and therapeutic cancer strategies addressed to either target mitochondria directly, or use mitochondria as mediators of apoptosis. While the first group includes drugs that act on glycolysis, β-oxidation, electron transport chain, mitochondrial permeability and the Bcl-2/IAP family protein, the second one consists of those drugs that cause cell death through the intrinsic apoptosis pathway by promoting ROS generation or by modulating mitochondrial protein involved in apoptosis induction.

Keywords: Apoptosis, metabolism, oxidative stress, therapy, anti-tumoral therapy, cardiolipin, DNA fragmentation, Vitamin E, caspases, glycolysis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [2002 - 2016]
Pages: 15
DOI: 10.2174/138161211796904803
Price: $65

Article Metrics

PDF: 29